Mineralys Therapeutics, Inc.
Business
Mineralys Therapeutics is a biopharmaceutical company developing lorundrostat, a proprietary oral aldosterone synthase inhibitor designed to treat hypertension and related cardiorenal conditions including chronic kidney disease and obstructive sleep apnea. The company has completed six clinical trials demonstrating efficacy and safety, with an NDA submitted in December 2025 and a FDA PDUFA target action date of December 22, 2026. Lorundrostat is being developed for use as add-on therapy in patients with uncontrolled or resistant hypertension despite existing antihypertensive medications. The company operates through a license from Tanabe Pharma Corporation and uses contract manufacturers for production.
Summary from 10-K filed 2026-03-12
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Research and development | 132 | 169 | 70 | 26 | |
| General and administrative | 39 | 24 | 14 | 5 | |
| Total operating expenses | 171 | 192 | 85 | 31 | |
| Loss from operations | −171 | −192 | −85 | −31 | |
| Interest income, net | 16 | 15 | 13 | 2 | |
| Other income | 0 | 5,000 | 3,000 | — | |
| Total other income, net | 16 | 15 | 13 | 2 | |
| Net loss | −155 | −178 | −72 | −30 | |
| Net loss per share attributable to common stockholders - basic (in USD per share) | −2.29 | −3.66 | −1.99 | −5.77 | |
| Net loss per share attributable to common stockholders - diluted (in USD per share) | −2.29 | −3.66 | −1.99 | −5.77 | |
| Weighted-average shares used to compute net loss per share attributable to common stockholders - basic (in shares) | 68 | 49 | 36 | 5 | |
| Weighted-average shares used to compute net loss per share attributable to common stockholders - diluted (in shares) | 68 | 49 | 36 | 5 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 173 | 114 | 49 | 88 | — | |
| Investments | 484 | 84 | 187 | — | — | |
| Prepaid and other current assets | 5 | 7 | 13 | 3 | — | |
| Total current assets | 661 | 205 | 249 | 113 | — | |
| Property and equipment, net | 38,000 | 53,000 | 0 | — | — | |
| Other assets | 382,000 | 499,000 | 51,000 | 2 | — | |
| Total assets | 662 | 206 | 252 | 114 | — | |
| Accounts payable | 2 | 479,000 | 601,000 | 2 | — | |
| Accrued liabilities | 13 | 14 | 10 | 6 | — | |
| Total current liabilities | 15 | 15 | 10 | 8 | — | |
| Commitments and contingencies (Note 4) | — | — | — | — | — | |
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of December 31, 2025 and 2024; 81,536,557 and 49,821,915 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 8,000 | 5,000 | 4,000 | 1,000 | — | |
| Additional paid-in capital | 1,104 | 494 | 366 | 540,000 | — | |
| Accumulated deficit | −457 | −303 | −125 | −53 | — | |
| Total stockholders equity | 647 | 191 | 241 | −52 | −23 | |
| Total liabilities and stockholders equity | 662 | 206 | 252 | 114 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Accretion of discount on held-to-maturity securities | −10 | −9 | −7 | −649,000 | |
| Stock-based compensation | 19 | 11 | 5 | 455,000 | |
| Depreciation and amortization | 59,000 | 43,000 | 0 | — | |
| Accrued interest receivable | −166,000 | 424,000 | −355,000 | 0 | |
| Prepaid, other current assets, and other assets | 2 | 5 | −10 | −2 | |
| Accounts payable and accrued liabilities | 427,000 | 4 | 2 | 3 | |
| Net cash used in operating activities | −142 | −166 | −81 | −29 | |
| Purchases of marketable securities | −815 | −373 | −348 | −72 | |
| Maturities of marketable securities | 425 | 489 | 188 | 50 | |
| Purchases of property and equipment | −15,000 | −96,000 | 0 | — | |
| Net cash provided by (used in) investing activities | −390 | 115 | −160 | −22 | |
| Proceeds from stock option exercises | 13 | 297,000 | 194,000 | 0 | |
| Proceeds from issuance of common stock for cash under employee stock purchase plan | 243,000 | 221,000 | 64,000 | 0 | |
| Payment of shelf offering costs | −391,000 | −435,000 | 0 | — | |
| Proceeds from issuance of common stock and pre-funded warrants in a private placement offering, net of offering costs | 0 | 116 | 0 | — | |
| Net cash provided by financing activities | 591 | 116 | 203 | 128 | |
| Net increase in cash and cash equivalents | 59 | 65 | −38 | 77 | |
| Offering costs included in accounts payable and accrued liabilities | 41,000 | 0 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Mineralys Therapeutics, Inc.'s CIK number?
Mineralys Therapeutics, Inc.'s SEC CIK number is 0001933414 (1933414). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Mineralys Therapeutics, Inc.'s SEC filings?
All of Mineralys Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Mineralys Therapeutics, Inc. last report earnings?
Mineralys Therapeutics, Inc. (MLYS) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001933414-26-000082). This is Mineralys Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Mineralys Therapeutics, Inc.'s most recent earnings 8-K?
Mineralys Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001933414-26-000082. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Mineralys Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →